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Abstract
Background: The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection
for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic
arthritis (JIA). Limited data from the patients’ perspective are available on the use of biologics in the treatment of
these chronic conditions and this evaluation was designed to collect data from patients who had been prescribed
etanercept for the first time. This manuscript describes the self-reported baseline characteristics and health-related
quality of life of patients prior to treatment. Follow-up data will be reported separately.
Methods: Patients throughout the United Kingdom prescribed etanercept were invited to participate in an
evaluation of their condition and treatment using a data collection tool consisting of a web-based system
supplemented by telephone reporting (PROBE). Outcome measures reported at baseline included demographic
data, the condition being treated, previous treatment with biologic agents and current and previous medications.
Questions modified from standard, validated quality of life questionnaires such as EQ-5D were incorporated and
patients made a global assessment of the severity of their own illness using the CGI-S scale.
Results: A total of 344 patients/carers/parents participated in the evaluation at baseline, 290 (84%) by online
questionnaire and 54 (16%) by telephone. Overall, the study population had a mean age of 53 years, was
predominantly female (62%) and 20% had been previously treated with a biologic agent. A total of 191 (56%)
patients were receiving treatment with etanercept for rheumatoid arthritis, 44 (13%) for psoriatic arthritis, 43 (13%)
for ankylosing spondylitis, 35 (10%) for psoriasis, 9 (3%) for known juvenile idiopathic arthritis (JIA) and 22 (6%) for
another condition/patient unsure/missing response. All patients were prescribed the 50 mg weekly dose of
etanercept except for 1 patient with JIA (40 mg) dose and 2 patients with psoriasis (100 mg). Thirty-eight percent
of patients with rheumatoid arthritis were not receiving treatment with methotrexate.
Conclusions: The baseline characteristics and health-related quality of life of first time users of etanercept can be
adequately described using self-reported patient data collected using an online questionnaire with a telephone
option (PROBE).
Background
Etanercept (Enbrel®, Pfizer) is a human tumour necrosis
factor alpha (TNF-a) receptor fusion protein produced
by recombinant DNA technology. It binds to TNF-a
and prevents its interaction with cell surface receptors,
thus interfering with the inflammatory cascade. In
adults, etanercept can be used to treat active, moderate
to severe rheumatoid arthritis, either in combination
with methotrexate when the response to standard dis-
ease modifying antirheumatic drugs (DMARDs) is inade-
quate, or as monotherapy, if methotrexate cannot be
tolerated or if the disease is severe, active and progres-
sive. Anti-TNF therapies, such as etanercept can slow
the rate of progression of joint damage, reduce symp-
toms such as joint pain, swelling and mobility and
improve physical functioning. Etanercept is also used to
treat other inflammatory conditions such as psoriasis,
ankylosing spondylitis, psoriatic arthritis and juvenile
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idiopathic arthritis (JIA) in patients who have had an
inadequate response to standard therapy. In adults, eta-
nercept is administered as a subcutaneous injection, 50
mg once weekly or 25 mg twice weekly [1].
Observational data on patients treated with anti-TNF
therapies for moderate to severe rheumatoid arthritis,
ankylosing spondylitis, psoriatic arthritis and other rheu-
matologic indications are available from the British
Society of Rheumatology Biologics Register (BSRBR,
[2]). The register captures information recorded by Con-
sultants on a patient’s current and previous treatments,
disease severity as assessed by American College of
Rheumatology (ACR) criteria and current disease activ-
ity based on the disease activity score-28 (DAS-28) at
baseline. A short form Consultant questionnaire is
repeated annually with information collected on events
of special interest. Patient-reported outcome data from
the EuroQoL [3] and Health Assessment Questionnaire
(HAQ, [4]) are collected at baseline and 6-monthly
intervals.
Naturalistic research has become increasingly impor-
tant in assessing the use of therapeutic interventions in
clinical practice. Many factors other than those related
to the properties of the intervention may influence how
it works in a real-life setting, such as the beliefs and
behaviour of patients, healthcare providers and general
healthcare characteristics.
This evaluation was designed to collect naturalistic
data directly from patients who have been prescribed
etanercept for the first time using the PROBE methodol-
ogy. PROBE has been developed as a self-reported data
collection tool by Patients Direct and has been used to
collect data in other therapy areas such as side effects
following H1N1 and/or seasonal influenza vaccination
and for a new product licensed for insomnia. It consists
of a web-based system supplemented by telephone
reporting for patients preferring this reporting mode.
The methodology is relatively inexpensive to administer,
allows data to be collected easily from specific target
groups and can be tailored to suit different types of
investigation. Furthermore, it allows the ‘baseline’
respondents to be contacted again to provide longitudi-
nal follow-up information, thus enabling patient-
reported outcomes on the effectiveness, healthcare
experience, adverse events and persistence of etanercept
treatment to be tracked.
Electronic collection of patient-reported outcome data
using web-based technology is becoming an established
way of gathering health data. However, patients who
respond on the Internet may not be typical of the gen-
eral population, potentially being younger, more edu-
cated and of a higher social class. By providing the
alternative option of participating using a Freephone
service, the PROBE methodology alleviates any problem
that the elderly or other groups may have in accessing
the Internet and allows a more representative popula-
tion to be obtained, which is vital for reducing bias. Ori-
ginal data used to perform this analysis is provided in
Additional file 1.
In this evaluation, the research methodology of
PROBE differs from that of the BSRBR as it is entirely
patient (or carer/parent) reported and has a wider
scope. Post-baseline data were collected on a patient’s
healthcare experience measured through questions such
as time between prescription and delivery of etanercept
and quality of injection training, and there were addi-
tional quality of life measures.
The overall aims of the evaluation were:
• To determine the baseline characteristics of
patients prescribed etanercept
• To evaluate the healthcare experience of patients
prescribed etanercept by assessing the service provi-
sion from hospital specialists through to home care
delivery and training.
• To measure patient-reported outcomes including
persistence with treatment, benefits of treatment and
adverse events
In this manuscript, a full description of the PROBE
methodology is given under “methods” below and the
baseline data are reported. Data on the healthcare
experience of patients prescribed etanercept and follow-
up data will be reported in separate manuscripts.
Methods
Study design
This evaluation was designed to collect naturalistic data
directly from patients prescribed etanercept using the
PROBE methodology consisting of a web-based system
supplemented by telephone reporting. It was conducted
throughout the United Kingdom by Patients Direct,
Glasgow.
Patients
Patients who had been newly prescribed etanercept by
their specialist between April and November 2009 were
invited to participate in the evaluation through leaflets.
These were distributed to approximately 1000 patients.
The initial supply of etanercept was delivered by a com-
pany providing nursing services in the patient’s home.
At the time of delivery, patients were provided with an
invitation letter and a written information sheet contain-
ing detailed information about the evaluation including
the website address of Patients Direct (http://www.
patientsdirect.net) and a 4-digit PIN code specific to
each patient. In addition, patients were given a support
pack designed by Wyeth/Pfizer, which contained written
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materials and an instructional DVD to educate patients
about the correct way to use etanercept. The project
and methodology were submitted to the National
Research Ethics Centre (NRES). They confirmed that
this project did not require formal approval.
Patient Reported Outcomes Based Evaluation (PROBE)
Web-based mode
Patients using the web-based mode of reporting logged
onto the secure website via the Enbrel section of http://
www.patientsdirect.net by entering the PIN code. They
were then prompted to choose a personal password.
Consent was obtained electronically and consenting
patients were asked to answer a questionnaire, which
took approximately 10 minutes to complete. Questions
were displayed in a logical sequence using radio buttons,
check boxes, drop down menus and free text for
responses. Many questions also had the option of ‘I am
not sure’. The layout of the online questionnaire
included ‘smart branding’ to switch to the next relevant
question and reduce complexity. For example, only
patients with known rheumatoid arthritis were asked
about their DAS-28. A summary of the information col-
lected at baseline is presented in Table 1. Patients were
asked to complete the baseline questions before they
had started treatment with Enbrel. If they had already
started treatment, they were instructed to answer the
questions as if it was before they had started treatment.
Telephone reporting
Patients without Internet access or those who preferred
to use the telephone were able to participate in the eva-
luation by using a Freephone number and speaking to a
research nurse. Verbal consent was obtained. The
research nurse went through the questions in the same
structured format, with visual analogue scales (VAS)
described by stating what the minimum and maximum
values represented and asking patients where they felt
they were on the scale. All responses were entered
directly into the web-based database. The research
nurse also provided telephone support to Internet users.
Follow-up data
The flexibility of the PROBE system allowed additional
data to be collected. After 2 weeks, 1 month and
monthly intervals up to 6 months, patients were con-
tacted by E-mail, text message or telephone and
reminded to revisit the website to answer further ques-
tions or to respond by telephone. An information and
consent page preceded collection of effectiveness
(patient symptoms), side effect and persistence data. No
longitudinal follow-up data are presented in this
manuscript.
A lower proportion of patients with rheumatoid
arthritis reported concomitant use of methotrexate at
baseline than expected. Therefore, patients responding
“no” to the question “Are you taking methotrexate”
were contacted to obtain further information on any
previous use of methotrexate and if relevant, their rea-
son for stopping treatment.
This requirement to contact patients to verify their
answers could not easily be foreseen in setting up the
project and illustrates the flexibility of the methodology.
Functional status and Quality of Life Instruments.
Functional status and Quality of Life Instruments
Electronic facsimiles of the following functional status
and quality of life instruments were used in the evalua-
tion. All patients were asked Clinical Global Impres-
sions-Severity of Illness (CGI-S) scale and EuroQol 5
dimensions (EQ-5D) questions. Patients with rheuma-
toid arthritis, JIA or psoriasis were also asked more dis-
ease specific questions from the HAQ, Child Health
Assessment Questionnaire (CHAQ) and Dermatology
Life Quality Index (DLQI) instruments respectively.
Clinical Global Impressions-Severity of Illness (CGI-S)
Functional status of all patients was assessed using the
CGI-S scale, which is a 7-point scale ranging from 1 =
normal to 7 = extremely ill [5]. This self-assessed eva-
luation of patients’ overall condition was in response to
the question: “Overall how bad do you consider your
condition now?
EuroQol 5 dimensions (EQ-5D)
Quality of life was assessed in all patients using the EQ-
5D descriptive system and the EQ visual analogue scale
(EQ VAS) questions developed by the EuroQol group
[3]. The EQ-5D descriptive system assesses 5 dimen-
sions (mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression) on a 3-point scale (1 = no
problems, 2 = some problems, 3 = severe problems).
Patients indicated which statements best described their
Table 1 Outcome measures collected at baseline
• Demographical details (first name, age, sex, E-mail, first part of post
code)
• Condition being treated
• Previous treatment with biologic agents
• Current medications including methotrexate
• Functional status and general quality of life
- CGI-S
- EQ-5D and EQ VAS
• Disease-specific quality of life
- HAQ for patients with rheumatoid arthritis
- CHAQ for patients with juvenile idiopathic arthritis (JIA)
- DSLI for patients with psoriasis
• DAS-28 for patients with rheumatoid arthritis
CGI-S Clinical Global Impression - Severity of Illness, CHAQ Child Health
Assessment Questionnaire, DAS-28 Disease Activity Score-28, DSLI
Dermatology Life Quality Index, EQ-5D EuroQol 5 dimensions, EQ VAS,
EuroQol visual analogue scale, HAQ Health Assessment Questionnaire
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health state on that day for each of the 5 dimensions. A
weighted health status index score was calculated for
the data by applying scores from the appropriate avail-
able ‘value sets’. A higher score indicates a better quality
of life, with a maximum value of 1, and zero represents
a health state equivalent to death. The EQ VAS records
a patient’s health state on a visual analogue scale where
the endpoints range from ‘best imaginable health state’
(100) to ‘worst imaginable health state’ (0). The conven-
tional, paper-based version of the EQ VAS uses a verti-
cal alignment similar to a thermometer. However, in the
web-based assessment, a horizontal visual analogue scale
was used and patients used a pointer to indicate how
good or bad their health state was on that day. In the
telephone assessment, a verbal description of the scale
was given and patients asked to provide a number
representing their health state. Both the web-based and
telephone reporting modes used the same wording for
the endpoints.
Health Assessment Questionnaire (HAQ)
The HAQ disability index (HAQ-DI) was used to assess
the level of disability in patients with rheumatoid arthri-
tis. It is based on 20 items in 8 domains: dressing, rising,
eating, walking, hygiene, reach, grip and usual activities
and includes questions on the use of aids or devices and
whether assistance is needed from another person [4].
Each item has 4 levels ranging from 0 = without any dif-
ficulty to 3 = unable to do, with standard scoring taking
the use of aids and devices or assistance from another
person into account. The mean of the domain scores
gives the disability index, which varies from 0 to 3
points (highest degree of incapacity).
Child Health Assessment Questionnaire (CHAQ)
The CHAQ was used to assess the functional ability of
children and adolescents with JIA to perform daily living
activities [6]. It is made up of 30 items in the same 8
domains as the HAQ-DI and uses a similar scoring sys-
tem. ‘Not applicable’ is available as an additional option
for each item as some items could not be applied to
young children. The CHAQ VAS Pain Scale question
was included to assess the severity of pain related to the
illness over the past week and was scored from 0 (no
pain) to 100 (very bad pain).
Dermatology Life Quality Index (DLQI)
The DLQI is a dermatology-specific instrument consist-
ing of 10 questions concerning the effect of the skin
problem on a patient’s quality of life over the previous
week [7].
Sample size and statistical methods
No formal sample size calculations were conducted
prior to the study, since the objective of the research
was exploratory, and data were being collected in a
novel manner with no prior knowledge of likely uptake
rates. However, to illustrate the value of the data, a sam-
ple size of 300 respondents provides sufficient informa-
tion to estimate prevalence figures with a 95%
confidence interval of no more than ±5.7%; within sub-
groups of 100 individuals, this precision is ±9.8%.
Statistical analyses were performed using Splus for Win-
dows v8.1. Baseline patient characteristics and responses
have been summarised descriptively. Post hoc analyses
were performed to compare the baseline characteristics of
Internet and telephone users using the Wilcoxon-Mann-
Whitney test and to compare the CGI-S and EQ-5D mea-
sures by the condition treated using both the Kruskal-
Wallis test and Analysis of Variance (ANOVA).
Results
Patient disposition
A total of 344 patients treated with etanercept
responded to the invitation to participate in the baseline
evaluation between April 2009 and April 2010, with 290
(84%) using the web-based mode and 54 (16%) using
the telephone (Table 2). The breakdown by reporting
mode and condition is shown in Figure 1. The rough
estimate of uptake was 34% based on distribution of
about 1,000 leaflets and assuming one leaflet per patient.
However, the actual number of patients who were eligi-
ble to participate is unknown. The respondents con-
sisted of patients (n = 331), carers (n = 6) and parents
(n = 7). There was a high response rate to questions at
baseline. The average response rate for questions asked
of all respondents was 95% (range 93% to 100%),
excluding the EQ-5D VAS question which was com-
pleted by only 46%. Original data used to perform this
analysis is provided in Additional file 2.
Patient characteristics and conditions
The baseline characteristics of the patients are given in
Tables 2 and 3, by reporting mode and condition
respectively. The majority of patients (191, 56%) were
receiving treatment with etanercept for rheumatoid
arthritis, with 35 (10%) patients receiving treatment for
psoriasis, 44 (13%) for psoriatic arthritis, 43 (12%) for
ankylosing spondylitis and 9 (3%) for known JIA. In
addition, 10 (2.9%) patients had another condition or
were unsure of their condition and 12 (3.5%) patients
had missing data for this question. The patients had a
mean age of 53 years and were predominantly female
(201/323, 62%), which was expected due to the higher
incidence of rheumatoid arthritis in females.
There were some differences in the baseline character-
istics of respondents using the Internet and telephone.
The mean age of patients completing the evaluation by
telephone was significantly higher than Internet respon-
dents (61.5 y vs. 51.4 y, p < 0.001). Patients with rheu-
matoid arthritis responding using the telephone were
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significantly older (64.4 y vs. 53.9 y, p < 0.001) and also
had a significantly higher level of disability than those
using the Internet, as assessed by the HAQ (1.68 vs.
1.97, p = 0.003).
Medications
Previous use of biologic agents
One fifth of patients participating in the evaluation had
been previously treated with a biologic agent. The TNF
inhibitor, adalimumab was the most commonly used
biologic (Table 4). Some patients (12%) were unsure
whether or not they had been treated with a biologic.
No patients had previously been treated with etanercept
as the baseline evaluation was carried out in patients
following their first prescription.
Methotrexate use
The current use of methotrexate and other medications
is given in Tables 5 and 6 respectively. Methotrexate
Table 2 Baseline characteristics of participants, by reporting mode
Internet Telephone Total
Completed, n (% of total) 290 (84.3%) 54 (15.7%) 344 (100%)
Completed by: n (%)
Patient 277 (95.5%) 54 (100%) 331 (96.2%)
Carer 6 (2.1%) 0 (0%) 6 (1.7%)
Parent 7 (2.4%) 0 (0%) 7 (2.0%)
Age, mean years (range) 51.4 (13-77)a 61.5 (35-82) 53.1 (13-82)
Sex, n (%) M/F 103/166 (38.3/61.7) 19/35 (35.2/64.8) 122/201 (37.8/62.2)
Diagnosis, n (%) [mean age, %F]
Rheumatoid arthritis 152 (79.6%) [53.9, 72%] 39 (20.4)% [64.4, 67%] 191 (100%)[56.0, 71%]
Psoriasis 31 (88.6%) [48.2, 52%] 4 (11.4%) [61.2, 75%] 35 (100%) [49.8, 62%]
Ankylosing spondylitis 40 (93.0%)[49.1, 25%] 3 (7.0%) [51.3, 33%] 43 (100%) [49.2, 26%]
Psoriatic arthritis 37 (84.1%) 50.3, 68%] 7 (15.9%) [51.9, 71%] 44 (100%) [50.5, 68%]
Otherb 30 (96.8%) [41.7, 63%] 1 (3.2%) [48.0, 0%] 31 (100%) [42.1, 62%]
Previous biologics
N 275 54 329
Any 59 (21.5%) 6 (11.1%) 65 (19.8%)
Adulimumab 43 (15.6%) 5 (9.3%) 48 (14.6%)
Infliximab 11 (4.0%) 1 (1.9%) 12 (3.6%)
Current medications
N 277 54 331
Methotrexate 120 (43.3%) 29 (53.7%) 149 (45.0%)
Sulfasalazine 46 (16.6%) 7 (13.0%) 53 (16.0%)
Prednisolone 55 (19.9%) 14 (25.9%) 69 (20.8%)
Quality of life
CGI-S
N 275 54 329
N ( %) ≥markedly ill) 184 (66.9%) 30 (55.6%) 214 (65.0%)
EQ-5D
N 265 54 (0.35)
EQ5D Index, Mean (SD) 0.41 (0.36) 0.45 (0.29) 0.42
N 139 20 159
EQ5D VAS, Mean (SD) 47.6 (23.0) 51.2 (21.8) 48.1 (22.8)
HAQ
N 151 190
Mean (SD) 1.68 (0.64)c 1.97 1.74 (0.65)
DLQI
N 31 4 35
Mean (SD) 15.5 (8.1) 11.8 (3.4) 15.0 (7.8)
a Statistically significant difference between Internet and telephone users, p < 0.001 (Wilcoxon test)
b Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition
missing (n = 12, 3.5%) to the question ‘What condition do you have that is being treated with Enbrel?’
c Statistically significant difference between Internet and telephone users, p = 0.003 (Wilcoxon test), p = 0.010 (t-test)
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was the most commonly taken second-line therapy for
all conditions (62% rheumatoid arthritis, 36% psoriatic
arthritis, 11% psoriasis, 42% other) except for ankylosing
spondylitis (7%), for which prednisolone was more com-
monly used (14%). The reasons for patients not taking
methotrexate were investigated further by contacting
patients who were not taking it at baseline. Overall, 57%
of these patients provided feedback. The most com-
monly reported reason for stopping methotrexate treat-
ment was given as ‘side effects’ (71%), followed by ‘lack
of effect’ (16%) and ‘stopped by doctor’ (12%).
Other medications
Prednisolone and sulfasalazine were commonly taken to
treat all the conditions other than psoriasis (Table 6).
Patients with psoriasis mainly used creams for the
condition at baseline (71%) and none of the patients had
undergone phototherapy treatment.
Etanercept dose
The mean weekly dose of etanercept prescribed was 50
mg (range 40 to 100 mg); the 40 mg dose was used in 1
patient with JIA and 100 mg was used by 2 patients
with psoriasis.
Functional status and quality of life
The CGI-S responses indicated that 65% of patients
(214/329) were at least markedly ill at baseline (Table
7). The general quality of life (EQ-5D Index and VAS
scores) and more disease specific measures (CHAQ,
DLQI, HAQ) are also shown in Table 6.
Patients with ankylosing spondylitis appear to rate
their quality of life as being worse than other patients
taking etanercept. This was in agreement with the
numerically lower mean CGI-S score of patients with
ankylosing spondylitis than those with other conditions.
However, whilst there was some evidence of a difference
in quality of life between the conditions, as assessed by
the mean EQ 5D Index scores (p = 0.043, Kruskal
-Wallis test, p = 0.259, ANOVA), there was no signifi-
cant difference between the CGI-S scores.
Disease Activity Score-28 (DAS-28)
Over 90% of patients (172/190) with rheumatoid arthri-
tis did not know their DAS-28 score. Of those who sta-
ted they did know their score, clearly many did not
understand or correctly recall it as many gave values
greater than 10 (mean 27.06, SD 36.96, range 4-105).
Discussion
Patient-reported outcome data are becoming extensively
used not only in clinical trials and epidemiological stu-
dies, but also in assessing patient care and adverse event
Figure 1 Pie chart of patients participating in the evaluation,
by condition and reporting mode. Percentages are given to the
nearest whole number. Blue: Rheumatoid arthritis - Internet Light
blue: Rheumatoid arthritis - Telephone Red: Ankylosing spondylitis -
Internet Pink: Ankylosing spondylitis - Telephone Dark green:
Psoriatic arthritis - Internet Light green: Psoriatic arthritis -
Telephone Brown: Psoriasis - Internet Orange: Psoriasis - Telephone
Yellow: Juvenile idiopathic arthritis/other - Internet No colour:
Juvenile idiopathic arthritis/other - Telephone.
Table 3 Demographic characteristics of participants completing the baseline evaluation, by condition
Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Psoriasis Other a Total
Participants, n (% of total) 191 (55.5%) 43 (12.5%) 44 (12.8%) 35 (10.2%) 31 (9.0%) 344 (100%)
Patient, n (%) 189 (99.0%) 43 (100.0%) 41 (93.2%) 33 (94.3%) 25 (80.6%) 331 (96.2%)
Carer, n (%) 2 (1.0%) 0 (0.0%) 2 (4.5%) 1 (2.9%) 1 (3.2%) 6 (1.7%)
Parent, n (%) 0 (0.0%) 0 (0.0%) 1 (2.3%) 1 (2.9%) 5 (16.1%) 7 (2.0%)
Sex
N [N missing] 189 [2] 43 [0] 41 [3] 33 [2] 17 [14] 323 [21]
Male, n (%) 55 (29.1%) 32 (74.4%) 13 (31.7%) 15 (45.5%) 7 (41.2%) 122 (37.8%)
Female, n (%) 134 (70.9%) 11 (25.6%) 28 (68.3%) 18 (54.5%) 10 (58.8%) 201 (62.2%)
Age
N [N missing] 189 [2] 43 [0] 41 [3] 33 [2] 17 [14] 323 [21]
Mean (SD) 56.0 (12.5) 49.2 (12.3) 50.5 (9.5) 49.8 (11.0) 42.1 (13.4) 53.1 (12.6)
Range 20.0-79.0 27.0-71.0 34.0-68.0 27.0-82.0 13.0- 68.0 13.0-82.0
a Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition
missing (n = 12, 3.5%) to the question ‘What condition do you have that is being treated with Enbrel?’
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reporting [8-12]. This evaluation describes the use of
PROBE as a method for gathering information on
patients prescribed a biological DMARD. It showed that
an online questionnaire with a telephone option avail-
able for respondents was an effective way of collecting
self-reported patient data. The importance of providing
telephone support was indicated by 16% of respondents
using this reporting mode. Telephone respondents gen-
erally had a similar baseline profile to Internet respon-
dents, but were significantly older. This was an expected
finding, as although Internet access is increasing in the
elderly, this group still lags behind other age groups in
Table 4 Number (%) of patients with prior treatment of a biologic agent
Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Psoriasis Other a Total
N [N missing] 188 [3] 43 [0] 44 [0] 35 [0] 19 [12] 329 [15]
No prior treatment 127 (67.6%) 28 (65.1%) 30 (68.2%) 24 (68.6%) 15 (78.9%) 224 (68.1%)
Unsure of prior treatment 24 (12.8%) 5 (11.6%) 6 (13.6%) 4 (11.4%) 1 (5.3%) 40 (12.2%)
Any prior treatment 37 (19.7%) 10 (23.3%) 8 (18.2%) 7 (20.0%) 3 (15.8%) 65 (19.8%)
Adalimumab 31 (16.5%) 5 (11.6%) 7 (15.9%) 2 (5.7%) 3 (15.8%) 48 (14.6%)
Infliximab 7 (3.7%) 4 (9.3%) 0 (0.0%) 1 (2.9%) 0 (0.0%) 12 (3.6%)
Anakinra 2 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.6%)
Abatacept 0 (0.0%) 1 (2.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%)
Rituximab 3 (1.6%) 1 (2.3%) 1 (2.3%) 0 (0.0%) 0 (0.0%) 5 (1.5%)
Efalizumab 1 (0.5%) 0 (0.0%) 0 (0.0%) 4 (11.4%) 0 (0.0%) 5 (1.5%)
a Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition
missing (n = 12, 3.5%) to the question ‘What condition do you have that is being treated with Enbrel?’
Table 5 Use of methotrexate at baseline
Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Psoriasis a Other b Total
N [N missing] 190 [1] 43 [0] 44 [0] 35 [0] 19 [12] 331 [13]
Taking methotrexate
No, n (%) 71 (37.4%) 38 (88.4%) 27 (61.4%) 31 (88.6%) 11 (57.9%) 178 (53.8%)
Unsure, n (%) 1 (0.5%) 2 (4.7%) 1 (2.3%) 0 (0.0%) 0 (0.0%) 4 (1.2%)
Yes, n (%) 118 (62.1%) 3 (7.0%) 16 (36.4%) 4 (11.4%) 8 (42.1%) 149 (45.0%)
Route of administration
Tablets, n (%) 97 (82.2%) 3 (100.0%) 11 (68.8%) 3 (75.0%) 6 (75.0%) 120 (80.5%)
Injection, n (%) 21 (17.8%) 0 (0.0%) 5 (31.2%) 1 (25.0%) 2 (25.0%) 29 (19.5%)
Weekly dose
N [N missing] 116 [2] 3 [0] 16 [0] 4 [0] 7 [1] 146 [3]
Mean (SD) 16.6 (6.8) 17.5 (2.5) 15.6 (7.3) 16.2 (9.7) 13.6 (8.9) 16.4 (6.9)
Range 2.5-30.0 15.0-20.0 2.5-25.0 2.5-25.0 2.5-25.0 2.5-30.0
Feedback received
Yes, n (% of not taking) 40 (56.3%) 21 (55.3%) 19 (70.4%) 16 (51.6%) 5 (45.5%) 101 (56.7%)
Ever prescribed c
No, n (%) 1 (2.5%) 18 (85.7%) 0 (0.0%) 5 (31.2%) 1 (20.0%) 25 (24.8%)
Unsure, n (%) 1 (2.5%) 1 (4.8%) 0 (0.0%) 1 (6.2%) 0 (0.0%) 3 (3.0%)
Yes, n (%) 38 (95.0%) 2 (9.5%) 19 (100.0%) 10 (62.5%) 4 (80.0%) 73 (72.3%)
Reason stopped d
Lack of effect, n (%) 6 (15.8%) 1 (50.0%) 1 (5.3%) 4 (40.0%) 0 (0.0%) 12 (16.4%)
Side effects, n (%) 27 (71.1%) 1 (50.0%) 16 (84.2%) 5 (50.0%) 3 (75.0%) 52 (71.2%)
Doctor stopped, n (%) 5 (13.2%) 0 (0.0%) 2 (10.5%) 1 (10.0%) 1 (25.0%) 9 (12.3%)
Unsure, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
a Twenty-five patients (71.4%) with psoriasis were also using creams for the condition at baseline, but none of the patients had undergone phototherapy
treatment.
b Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition
missing (n = 12, 3.5%) to the question ‘What condition do you have that is being treated with Enbrel?
c Data for feedback responders (Respondents answering “no” to the question “ Are you taking methotrexate” at baseline and providing feedback on any previous
use)
d Data for feedback responders ever prescribed methotrexate (Feedback respondents answering “yes” to the question “ Have you ever been prescribed
methotrexate”)
Wade et al. BMC Medical Research Methodology 2011, 11:91
http://www.biomedcentral.com/1471-2288/11/91
Page 7 of 10
Internet usage [13]. Anecdotal evidence also suggested
that many respondents required telephone reassurance
to lead them through the initial questions, but thereafter
reverted to self-completion. Hence, telephone access
was important in helping to gain a representative
population of first time users of etanercept. Although
the respondents were mainly the patients themselves, a
small proportion (3%), was the patient’s parent or carer,
highlighting that information can be gathered success-
fully from other parties when relevant.
Table 6 Current medications other than methotrexate used to treat condition at baseline
Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Psoriasis Other a Total
N [N missing] 190 [1] 43 [0] 44 [0] 35 [0] 19 [12] 331 [13]
Sulfasalazine, n (%) 41 (21.6%) 4 (9.3%) 6 (13.6%) 0 (0.0%) 2 (10.5%) 53 (16.0%)
Leflunomide, n (%) 14 (7.4%) 0 (0.0%) 4 (9.1%) 0 (0.0%) 0 (0.0%) 18 (5.4%)
Prednisolone, n (%) 53 (27.9%) 6 (14.0%) 5 (11.4%) 1 (2.9%) 4 (21.1%) 69 (20.8%)
Ciclosporin, n (%) 2 (1.1%) 0 (0.0%) 1 (2. 3%) 1 (2.9%) 1 (5.3%) 5 (1.5%)
Acitretin, n (%) 3 (1.6%) 0 (0.0%) 0 (0.0%) 2 (5.7%) 0 (0.0%) 5 (1.5%)
N [N missing] - - - 35 [0] - 35 [309]
Creams for psoriasis - - - 25 (71.4%) - 25 (71.4%)
Phototherapy - - - 0 (0%) - 0 (0%)
a Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition
missing (n = 12, 3.5%) to the question ‘What condition do you have that is being treated with Enbrel?
Table 7 Number (%) of patients with functional status and quality of life measures at baseline
Score Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Psoriasis Other a Total
CGI-Severity
N [N missing] 190 [1] 43 [0] 42 [2] 35 [0] 19 [12] 329 [15]
Extremely ill 19 (10.0%) 0 (0.0%) 3 (7.1%) 5 (14.3%) 4 (21.1%) 31 (9.4%)
Severely ill 39 (20.5%) 15 (34.9%) 3 (7.1%) 8 (22.9%) 4 (21.1%) 69 (20.9%)
Markedly ill 66 (34.7%) 18 (41.9%) 17 (40.5%) 10 (28.6%) 3 (15.8%) 114 (34.7%)
Moderately ill 45 (23.7%) 7 (16.3%) 14 (33.3%) 5 (14.3%) 4 (21.1%) 75 (22.8%)
Mildly ill 13 (6.8%) 3 (7.0%) 3 (7.1%) 4 (11.4%) 2 (10.5%) 25 (7.6%)
Borderline 4 (2.1%) 0 (0.0%) 2 (4.8%) 3 (8.6%) 1 (5.3%) 10 (3.0%)
Normal 4 (2.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.3%) 5 (1.5%)
Mean (SD) b 3.12 (1.28) 2.95 (0.90) 3.40 (1.13) 3.11 (1.49) 3.16 (1.77)
EQ VAS
N [N missing] 85 [106] 22 [21] 25 [19] 21 [14] 6 [25] 159 [185]
Mean (SD) b 49.5 (22.4) 42.2 (23.8) 45.6 (19.2) 50.7 (25.6) 50.5 (30.8) 48.1 (22.8)
Range 8.0-100.0 6.0-90.0 8.0-85.0 5.0-90.0 20.0-92.0 5.0-100.0
EQ-5D Index
N [N missing] 181 [10] 43 [0] 43 [1] 34 [1] 18 [13] 319 [25]
Mean (SD) c 0.40 (0.34) 0.37 (0.37) 0.42 (0.32) 0.52 (0.39) 0.51 (0.40) 0.42 (0.35)
Range -0.24-1.00 -0.24-1.00 -0.24-0.80 -0.48-1.00 -0.35-1.00 -0.48-1.00
Disease specific HAQ Score DLQI Score CHAQ Score
N [N missing] 190 [1] - - 35 [0] 9 [22]
Mean (SD) 1.74 (0.65) - - 15.0 (7.8) 1.35 (0.54)
Range 0.00-3.00 - - 3.0-30.0 0.50-2.25
CHAQ Pain Score
N [N missing] - - - - 8 [23]
Mean (SD) - - - - 49.1 (30.1)
Range - - - - 7.0-90.0
a Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition
missing (n = 12, 3.5%) to the question ‘What condition do you have that is being treated with Enbrel?
b No significant differences in mean CGI-S or EQ-5D VAS scores between conditions using the Kruskal-Wallis test or ANOVA.
c No significant differences in mean CGI-S or EQ-5D VAS scores between conditions using the Kruskal-Statistically significant differences in EQ-5D Index scores
between the conditions using the Kruskal-Wallis test (p = 0.043), but not with ANOVA, p = 0.259.
CHAQ Child Health Assessment Questionnaire (for patients with juvenile idiopathic arthritis), CGI Clinical Global Impression, DLQI Dermatology Life Quality Index
(for patients with psoriasis), EQ EuroQoL, HAQ Health Assessment Questionnaire (for patients with rheumatoid arthritis), VAS Visual analogue scale
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The evaluation was conducted in 344 patients
throughout the United Kingdom who had been pre-
scribed etanercept, with the geographical spread of
patients confirmed by the first part of their postcode. As
expected due to the conditions under treatment, the
majority of the patients (69% with sex recorded) who
participated in the evaluation were women.
Patients with rheumatoid arthritis had a mean age of
55.9 years and 70.5% were women. This closely matched
the characteristics recently reported in an epidemiologi-
cal study with 466 patients (mean age 55.6 years, 69%
women, [14]). It is reassuring that the population cap-
tured in this evaluation using Internet technology and
telephone reporting reflects that of the existing litera-
ture. However, there was a significant difference
between the baseline characteristics of those responding
by telephone and the Internet, with those responding by
telephone significantly older and more disabled by the
condition. Again, this illustrates the importance of the
telephone reporting system in limiting bias by widening
participation and enabling information to be gathered
from patients who may lack Internet access.
The CGI-S responses of patients with rheumatoid
arthritis showed that 89% considered themselves at least
moderately ill. This reflected responsible prescribing with
etanercept given according to the license for the treat-
ment of moderate to severe rheumatoid arthritis. How-
ever, the proportion of patients with rheumatoid arthritis
not receiving treatment with methotrexate was consider-
ably higher than expected (38%). Feedback requested
from patients not currently taking methotrexate had
shown that side effects were the main reason for stopping
treatment. The majority of patients contacted for addi-
tional feedback responded illustrating their positive inter-
action with Patients Direct and the potential for
obtaining further information in this manner.
It is also worth noting that very few patients with
rheumatoid arthritis and prescribed etanercept were
aware of their DAS-28 score, which needs redressing if
patients are to take a more active role in managing their
own healthcare.
National Institute of Clinical Excellence (NICE) guide-
lines (TA130), which were in place during the evaluation
stated that patients with rheumatoid arthritis would not
be able to try a second TNF inhibitor if their first
attempt failed, unless therapy was withdrawn due to an
adverse event [15]. NICE have since issued guidelines
(TA195, 2010) allowing the use of a second TNF inhibi-
tor [16]. As 21% of patients participating in the evalua-
tion had previously received treatment with adalimunab
or infliximab, this would appear to indicate that switch-
ing to a second TNF inhibitor was accepted practice
before the update from NICE.
Limitations
There are a number of limitations with the evaluation.
One of the limitations is that the number of patients eli-
gible to participate is unknown as the precise number of
leaflets distributed is only a rough estimate. Hence, the
estimated uptake rate of 34% is imprecise and this may
result in recruitment bias between patients responding
to the invitation and non-responders.
Internet usage is associated with various socioeco-
nomic and demographic factors including age, sex, loca-
tion and education [13]. Hence, a disadvantage with
data collected using web technology is the tendency for
users not to be representative of the target population.
This is largely overcome by having a telephone option.
However, there may be some disadvantages from group-
ing together these two modes of reporting as there may
be differences in responses between telephone and
Internet respondents. Questions were completed more
fully and the mean age was higher in respondents using
the telephone option rather than the Internet. It is also
known that certain side effects such as emotional dis-
tress and problems with sexual function are less likely
to be reported as side effects over the telephone com-
pared with the Internet. Questions concerning unusual
symptoms affecting sexual function were asked at the
follow up time points, but were not part of the baseline
assessment.
There may also be some concerns about grouping
reports from patients with those of their parents or
carers, although these represented only a small contribu-
tion of the overall sample size (4%). Their inclusion
allowed information to be collected on young children
with JIA and patients more disabled by their condition.
The authors felt that including parent/carer reported
data in the evaluation would lead to less bias than from
their exclusion.
The user satisfaction and acceptability of PROBE and
ease of responding to the questions asked should also
have been assessed.
Conclusions
The baseline characteristics and health-related quality of
life of first time users of etanercept can be adequately
described using self-reported patient data collected
using an online questionnaire with a telephone option
(PROBE).
Baseline data obtained from patients with rheuma-
toid arthritis using this methodology are similar to
those reported in the literature. Self-reported data indi-
cates that patients with rheumatoid arthritis need to
better informed of their DAS-28 score and that their
concomitant use of methotrexate is lower than
expected.
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Additional material
Additional File 1: Word document Breakdown of telephone,
internet and all responses on baseline characteristics.
Additional File 2: Word document Breakdown of question
completion by telephone, internet and all respondents.
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